Crispr Therapeutics shares tumble after significant earnings miss
Investing.com -- Aehr Test Systems (NASDAQ:AEHR) shares dropped 20% after the semiconductor equipment maker reported a decline in fiscal fourth-quarter revenue compared to the same period last year.
The California-based company posted revenue of $14.1 million for the quarter, down from $16.6 million in the year-earlier period. Aehr also reported a net loss of $2.9 million, a significant reversal from the GAAP net income of $23.9 million it recorded in the same quarter of the previous fiscal year.
In a press release, management cited ongoing challenges affecting order timing, stating: "We continue to experience some timing-related delays in order placements due to tariff-related uncertainty, particularly in our first quarter."
The company has opted to maintain a cautious approach to its financial outlook. Management indicated they are "not reinstating specific guidance beyond what we have already stated, which is that we anticipate order growth across all our segments this fiscal year with the possible exception of silicon carbide."
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.